findmyKOL

Susan Grossman, MDQ

Basic profile

SUNY Downstate Health Sciences University

ORCIDNone on fileNPI
RegionStaten Island, NY · NortheastSpecialtyNephrologyFocusNephrology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH funding1993–1994Why? →

Susan Grossman is a Nephrology physician affiliated with SUNY Downstate Health Sciences University. OpenAlex indexes 24 publications with 876 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
24publications

Distinct works indexed by OpenAlex.

876citations

Total citations across indexed works.

8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 1993–1994

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1366 Victory Blvd
Staten Island, NY 103013948

Telephone

718-273-3400

Provider last certified this registry record 20 May 2021.

View the NPPES registry record

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    36%
    Statin9.8%
    Atorvastatin Calcium66%Rosuvastatin Calcium17%Pravastatin Sodium16%
    Part D<11 patients
    Calcium channel blocker5.9%
    Amlodipine Besylate79%Amlodipine Besylate-Benazepril21%
    Part D<11 patients

    + 7 more classes in this area

  • Nervous system

    25.1%
    Opioid Agonist9.6%
    Oxycodone-Acetaminophen73%Oxycodone Hcl27%
    Part D<11 patients
    Gabapentinoids4.8%
    Gabapentin69%Pregabalin31%
    Part D<11 patients

    + 6 more classes in this area

  • Metabolism & gastrointestinal

    20.5%
    SGLT2 inhibitor11.1%
    Farxiga55%Jardiance45%
    Part D<11 patients
    Biguanide (metformin)2.5%
    Metformin Hcl100%
    Part D<11 patients

    + 4 more classes in this area

Where care is delivered (Part B)63% facility · 37% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 19931994 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”